CANCER DRUG DEVELOPMENT PIPELINE
Oncology Drug Pipeline & Cancer Clinical Trials
Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.
Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.
PF-08046045 (35T) | New project
Advanced Solid Tumors and Lymphomas (Biologic)
CD-30 directed antibody-tripeptide MMAE conjugate
PF-08046049 (BB228) | New project
Advanced Melanoma and Other Solid Tumors (Biologic)
CD228-directed antibody-Anticalin bispecific protein
PADCEV (enfortumab vedotin) | New project
BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Biologic)
Nectin-4 directed antibody-drug conjugate
PF-07826390 (LILRB1/2) | New project
Advanced Solid Tumors (Biologic)
LILRB1/2 bispecific IgG1 antibody
PF-08046876 (B6C) | Project advanced
Advanced Solid Tumors (Biologic)
Integrin beta-6-directed antibody-drug conjugate
PF-08046032 (CD25V) | New project
Advanced Solid Tumors (Biologic)
CD25V directed antibody-drug conjugate
PF-08046037 (PDL1iT) | New project
Advanced Solid Tumors (Biologic)
Immunostimulatory Drug Conjugate (ISAC) targeted to PD-L1 with a TLR7 agonist payload
PF-08046031 (CD228V) | New project
Advanced Melanoma and other Solid Tumors (Biologic)
CD228V directed antibody-drug conjugate
PF-07985045 (KRAS) | New project
Advanced Solid Tumors
selective KRAS inhibitor
PF-08052666 (MesoC2) | New project
Advanced Solid Tumors (Biologic)
mesothelin-targeted antibody-drug conjugate
PF-07934040 (KRAS) | New project
Advanced Solid Tumors
selective KRAS inhibitor
PF-08046044 (35C) | New project
Advanced Solid Tumors (Biologic)
CD30-directed antibody TOPO1 drug conjugate
sigvotatug vedotin | New project
Advanced Solid Tumors (Biologic)
Integrin beta-6-directed antibody-drug conjugate
PF-08046050 (CEACAM5C) | New project
Advanced Solid Tumors (Biologic)
CEACAM5-directed antibody-drug conjugate
PF-08046040 (CD70) | New project
Myelodysplastic Syndrome and Acute Myeloid Leukemia (Biologic)
Non-fucosylated CD70-directed antibody
PF-08046052 (EGFRd2) | New project
Advanced Solid Tumors (Biologic)
EGFR-targeted bispecific gamma delta T-cell engager
TIVDAK (tisotumab vedotin) | New project
Recurrent or Metastatic Cervical Cancer (TV-205) (Biologic)
Tissue Factor-directed antibody-drug conjugate
PF-06940434 | New project
Advanced Solid Tumors (Biologic)
Integrin alpha-V/beta-8 antagonist
TUKYSA (tucatinib) | New project
HER2+ Gastrointestinal Cancers (SGNTUC-024)
HER2 tyrosine kinase inhibitor
prifetrastat (PF-07248144) + atirmociclib (PF-07220060) | New project
Breast Cancer Metastatic
KAT6 epigenetic modifier + CDK4 inhibitor
PF-07799544 | New project
Advanced Solid Tumors
MEK brain penetrant inhibitor
PF-07799933 | New project
Advanced Solid Tumors
BRAF Class 1 and Class 2 inhibitor
tegtociclib (PF-07104091) + atirmociclib | New project
Breast Cancer Metastatic
CDK2 + CDK4 inhibitors
prifetrastat (PF-07248144) | New project
Breast Cancer Metastatic
KAT6 epigenetic modifier
tegtociclib (PF-07104091) | New project
Breast Cancer Metastatic
CDK2 inhibitor
SSGJ-707 (PF-08634404) | New project
1L Metastatic Colorectal Cancer (Biologic)
PD-1xVEGF Bispecific Antibody
SSGJ-707 (PF-08634404) | New project
1L Non-Small Cell Lung Cancer (non-squamous) (Biologic)
PD-1xVEGF Bispecific Antibody
SSGJ-707 (PF-08634404) | New project
1L Non-Small Cell Lung Cancer (squamous) (Biologic)
PD-1xVEGF Bispecific Antibody
atirmociclib | New project
Early Breast Cancer
CDK4 inhibitor
atirmociclib | New project
2L HR+/HER2- Metastatic Breast Cancer (FourLight-1)
CDK4 inhibitor
disitamab vedotin | New project
Locally Advanced or Metastatic Solid Tumors with HER2 Expression (Biologic)
HER2-directed antibody-drug conjugate
disitamab vedotin | New project
2L+ Metastatic Urothelial Cancer with HER2 Expression (Biologic)
HER2-directed antibody-drug conjugate
TUKYSA (tucatinib) | New project
Locally Advanced or Metastatic Solid Tumors with HER2 Alterations
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | New project
2L+ HER2+ Metastatic Breast Cancer (HER2CLIMB-04)
HER2 tyrosine kinase inhibitor
TIVDAK (tisotumab vedotin) | New project
Advanced Solid Tumors (TV-207) (Biologic)
Tissue Factor-directed antibody-drug conjugate
PADCEV (enfortumab vedotin) | New project
Locally Advanced or Metastatic Solid Tumors (EV-202) (Biologic)
Nectin-4 directed antibody-drug conjugate
maplirpacept (TTI-622) | New project
Hematological Malignancies (Biologic)
CD47-SIRPa fusion protein
vepdegestrant (ARV-471) | New project
ER+/HER2- Neoadjuvant Breast Cancer
ER-targeting PROTAC protein degrader
PF-08046054 (PDL1V) | Project advanced
2L+ Non-Small Cell Lung Cancer (PADL1NK-005) (Biologic)
PD-L1-directed antibody-drug conjugate
prifetrastat (PF-07248144) | Project advanced
2L/3L HR+/HER2- Metastatic Breast Cancer (KATSIS-1)
KAT6 epigenetic modifier
atirmociclib (PF-07220060) | New project
1L HR+/HER2- Metastatic Breast Cancer (FourLight-3)
CDK4 inhibitor
mevrometostat (PF-06821497) + enzalutamide | Project advanced
1L Metastatic Castration-Sensitive Prostate Cancer NHT naive (MEVPRO-3)
EZH2 inhibitor + androgen receptor inhibitor
mevrometostat (PF-06821497) + enzalutamide | New project
1L Metastatic Castration Resistant Prostate Cancer NHT naive (MEVPRO-2)
EZH2 inhibitor + androgen receptor inhibitor
mevrometostat (PF-06821497) + enzalutamide | New project
1/2L Metastatic Castration Resistant Prostate Cancer post-Abiraterone (MEVPRO-1)
EZH2 inhibitor + androgen receptor inhibitor
disitamab vedotin (PF-08046051) | New project
1L HER2 (=IHC1+) Metastatic Urothelial Cancer (DV-001) (Biologic)
HER2-directed antibody-drug conjugate
TUKYSA (tucatinib) | New project
1L HER2+ Metastatic Colorectal Cancer(MOUNTAINEER-03)
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | New project
1L HER2+ Maintenance Metastatic Breast Cancer (HER2CLIMB-05)
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | New project
2L/3L HER2+ Metastatic Breast Cancer (HER2CLIMB-02)
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | New project
HER2+ Adjuvant Breast Cancer (CompassHER2 RD)
HER2 tyrosine kinase inhibitor
PADCEV (enfortumab vedotin) | New project
Cisplatin-Eligible Muscle-Invasive Bladder Cancer (EV-304) (Biologic)
Nectin-4 directed antibody-drug conjugate
sigvotatug vedotin (PF-08046047) | Project advanced
1L Metastatic Non-Small Cell Lung Cancer (mNSCLC) (tps high) (Be6A LUNG-02) (Biologic)
Integrin beta-6-directed antibody-drug conjugate
sigvotatug vedotin (PF-08046047) | New project
2L+ Metastatic Non-Small Cell Lung Cancer (mNSCLC) (Be6A LUNG-01) (Biologic)
Integrin beta-6-directed antibody-drug conjugate
ELREXFIO (elranatamab-bcmm) | New project
2L+ post-CD38 Relapsed Refractory Multiple Myeloma (MM-32) (Biologic)
BCMA-CD3 bispecific antibody
ELREXFIO (elranatamab-bcmm) | New project
Newly Diagnosed Multiple Myeloma Transplant-Ineligible (MM-6) (Biologic)
BCMA-CD3 bispecific antibody
ELREXFIO (elranatamab-bcmm) | New project
Newly Diagnosed Multiple Myeloma Post-Transplant Maintenance (MM-7) (Biologic)
BCMA-CD3 bispecific antibody
ELREXFIO (elranatamab-bcmm) | New project
Relapsed/Refractory Multiple Myeloma Double-Class Exposed (MM-5) (Biologic)
BCMA-CD3 bispecific antibody
TALZENNA (talazoparib) | New project
Combo w/ XTANDI (enzalutamide) for DNA Damage Repair (DDR)-Deficient Metastatic Castration Sensitive Prostate Cancer (TALAPRO-3)
PARP inhibitor
IBRANCE (palbociclib) | New project
ER+/HER2+ Metastatic Breast Cancer(PATINA) (BREAKTHROUGH - U.S.)
CDK 4,6 kinase inhibitor
PADCEV (enfortumab vedotin) | Project advanced
Cisplatin-Ineligible/Decline Muscle-Invasive Bladder Cancer (EV-303) (Biologic) (PRIORITY - U.S.)
Nectin-4 directed antibody-drug conjugate
vepdegestrant (ARV-471) | Project advanced
ER+/HER2- Metastatic Breast Cancer ESR1mu (VERITAC 2)
ER-targeting PROTAC protein degrader
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG) | New project
High-Risk Non-Muscle-Invasive Bladder Cancer (CREST) (Biologic)
Anti-PD-1